Assay

Italy Automated Microbiology Market Report 2023-2028 - Growth Opportunities, 2023 Supplier Shares by Assay, Five-Year Segmentation Forecasts - ResearchAndMarkets.com

Retrieved on: 
Friday, April 5, 2024
Biotechnology, Health, Medical Devices, Blood culture, Emerging technologies, Assay, SWOT analysis, Microbiology, Retail

The "2023-2028 Italy Automated Microbiology Market - Growth Opportunities, 2023 Supplier Shares by Assay, Five-Year Segmentation Forecasts - Competitive Strategies and SWOT Analysis, Instrumentation Pipeline, Emerging Technologies, Market Barriers and Risks" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "2023-2028 Italy Automated Microbiology Market - Growth Opportunities, 2023 Supplier Shares by Assay, Five-Year Segmentation Forecasts - Competitive Strategies and SWOT Analysis, Instrumentation Pipeline, Emerging Technologies, Market Barriers and Risks" report has been added to ResearchAndMarkets.com's offering.
  • This report is an analysis of the major business opportunities emerging in the automated microbiology market during the next five years.
  • The report examines key trends in the Italian automated microbiology market; reviews current and emerging assays; analyzes potential applications of innovative diagnostic technologies; forecasts volume and sales for molecular diagnostic, microbial identification, antibiotic susceptibility, blood culture, urine screening and immunodiagnostic procedures, as well as over 100 infectious disease tests by assay, application, market segment, profiles leading players and potential market entrants; and suggests alternative business expansion strategies for suppliers.

Aurigene Pharmaceutical Services Ltd. introduces Aurigene.AI™, an artificial intelligence (AI) and machine learning (ML) assisted drug discovery platform

Retrieved on: 
Wednesday, April 3, 2024
Software, Biotechnology, Pharmaceutical, Health, Artificial Intelligence, Data Management, Health Technology, Technology, Cloud, Google Cloud, Algorithm, Database, Drug discovery, Drug, CADD, DMTA, AI, Assay, Confidentiality, Therapy, Machine learning, Medical device

Aurigene Pharmaceutical Services Limited (Aurigene), a contract research, development, and manufacturing services organization and a Dr. Reddy’s Laboratories company, introduces Aurigene.AI, an AI and ML-assisted platform for accelerating drug discovery projects from hit identification to candidate nomination.

Key Points: 
  • Aurigene Pharmaceutical Services Limited (Aurigene), a contract research, development, and manufacturing services organization and a Dr. Reddy’s Laboratories company, introduces Aurigene.AI, an AI and ML-assisted platform for accelerating drug discovery projects from hit identification to candidate nomination.
  • Aurigene.AI combines advanced physics-based simulation, generative and predictive AI models, and CADD (Computer-Aided Drug Design) in one platform, allowing users to pick the appropriate algorithms for a given application.
  • The modular platform also consists of a meticulously curated database of 180 million compounds and 1.6 million validated bioassay data points.
  • Akhil Ravi, CEO, Aurigene Pharmaceutical Services Ltd., said, “We are committed to continually advancing our service experience and providing innovative end-to-end solutions to our global partners.

Global Proteomic Biomarker Analytics Market Analysis Report 2024 with Executive & Consultant Guides; Including Customized Forecasting and Analysis - ResearchAndMarkets.com

Retrieved on: 
Friday, March 29, 2024
Health, Biotechnology, Illumina, Assay, Place, Proteomics, Genomics, Research, Cancer, Application

The "Global Proteomic Biomarker Analytics Market Forecasts by Application, Technology, Product, and Place, with Executive & Consultant Guides; Including Customized Forecasting and Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Proteomic Biomarker Analytics Market Forecasts by Application, Technology, Product, and Place, with Executive & Consultant Guides; Including Customized Forecasting and Analysis" report has been added to ResearchAndMarkets.com's offering.
  • Where genomics couldn't find all the answers proteomics is stepping up to the plate.
  • Proteomic Biomarker Analytics is just finding its feet, but the opportunity is to understand the front line players, the actual proteins and protein complexes, that do the work of managing cellular life.
  • The report forecasts the market size out for five years for a number of different market segments.

Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024

Retrieved on: 
Friday, March 8, 2024
Assay, Cancer, JNK, NLRP3, AACR, IIS, Biochemistry, Cellular, Therapy, Reactive oxygen species, Tumor microenvironment, Patient, ROS, Research, Pharmaceutical industry

“The ability to impact multiple targets is an important characteristic of Onconova’s two lead clinical programs, rigosertib and narazaciclib.

Key Points: 
  • “The ability to impact multiple targets is an important characteristic of Onconova’s two lead clinical programs, rigosertib and narazaciclib.
  • We are pleased to present new preclinical studies that explore the molecular targets for rigosertib, in clinical development through a series of investigator initiated studies (IIS),” commented Steven Fruchtman, M.D., President and Chief Executive Officer of Onconova.
  • “The studies provide additional prospective on the main cellular pathways impacted by rigosertib, including RAS-MAPK signaling and reactive oxygen species (ROS)-related proteins.
  • Conclusions: This work identified a series of cellular and inflammatory targets that may be affected by rigosertib.

Ceapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceutical Base Business

Retrieved on: 
Friday, February 23, 2024
Litre, Arrangement, Health Canada, OBG, TSX, Data monitoring committee, LDL, MBA, Assay, Safety, Cheese, University, Food engineering, University of Alberta, CZO, Infant, NPN, Journal, Protein, Clinical trial, Whey, Canada Business Corporations Act, Tissue, Water, Dietary supplement

EDMONTON, Alberta, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), today provided an update on its progress across its current business.

Key Points: 
  • EDMONTON, Alberta, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), today provided an update on its progress across its current business.
  • In addition to the proposed Arrangement, the Company continues to execute on progress across its ongoing development projects, as detailed below.
  • “We continue to make promising progress across all areas of our business.
  • Given the recent developments, we anticipate that all key success factors will align to expand our business model.

Introducing Assay Performance Monitoring for the Automated Assessment of Assay Data Quality in Real Time

Retrieved on: 
Monday, March 4, 2024
Bias, Artificial intelligence, Information management, Drug discovery, Assay, Quality control, ELN, Surface plasmon resonance, Classification, Organization, Automation, BLI, SPR, Fine chemical

BASEL, Switzerland, March 4, 2024 /PRNewswire-PRWeb/ -- Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced a new release of Genedata Screener®, its enterprise platform for automated assay data analytics and consolidated assay information management across an enterprise. The new version features as a new module, Assay Performance Monitoring, the first commercially available solution for monitoring assay data quality in the context of historical data. Included in the most comprehensive assay analytics platform on the market, Genedata Screener 21 sets new standards for data quality assessment and automated data processing that produce higher result quality, accelerated workflows coupled with increased consistency, improved scientific efficiency, and shortened timelines for molecule discovery and development.

Key Points: 
  • The new version features as a new module, Assay Performance Monitoring, the first commercially available solution for monitoring assay data quality in the context of historical data.
  • Developed in close collaboration with leading biopharma companies, Genedata Screener 21 offers a new integrated solution for continuous assessment of assay quality, enabling the automated identification of experimental issues without delay.
  • Without a suitable enterprise solution, assay scientists spend hours manually compiling assay performance data, often bouncing between software tools.
  • Routine assay performance assessment in Screener using the new Assay Performance Monitoring module follows industry best-practices and ensures that assay quality standards are met without the need for manual data compilation.

Globex Exploration Update on Virgin Mountain Rare Earth & Beryllium Project, Arizona, USA

Retrieved on: 
Tuesday, February 13, 2024
Thulium, Virginity, Yttrium, GMX, Beryllium, Radioactive decay, Geo, Erbium, Niobium, Density, AAL, Terbium(III) oxide, Gadolinium, Toronto Stock Exchange, ASARCO, Ytterbium, LREE, Silver, Tantalum, Assay, Dysprosium, Wolverine, Terbium, Holmium, Virgin Mountain, Asarco, Chrysoberyl, Uranium, Beryl, Geology, Element, REE, Virgin Mountains, Lutetium, Anomaly, ICP-OES, Rare-earth element

The Virgin Mountain rare earth & beryllium property is located in the Arizona portion of the Virgin Mountain range, about 120 km northeast of Las Vegas, Nevada.

Key Points: 
  • The Virgin Mountain rare earth & beryllium property is located in the Arizona portion of the Virgin Mountain range, about 120 km northeast of Las Vegas, Nevada.
  • Past exploration activities for uranium and later for rare earth elements (REE) initiated in the 1940’s and ended in 1991.
  • In the 1950’s and 1960’s the Virgin Mountains Be-bearing pegmatites had been explored intensely for beryllium, but never came into production.
  • Rare Earth (REE) ± U & Th mineralization is hosted in migmate-gneiss and interlayered thin schist layers, locally also in pegmatite dikes.

Pan American Energy Announces Further Drill Results at the Big Mack Lithium Project, Including Intersecting 16.00 m at 1.55% Li2O

Retrieved on: 
Monday, February 12, 2024
Bias, Calibration, Assay, ISO, Competence, ALS, News, UAV, QA/QC, ISO/IEC 17025, ISO 9001, ICP-MS, ICP-AES, Gravity anomaly

Visual core logging indicates that the predominant host mineral for the Big Mack pegmatites is petalite.

Key Points: 
  • Visual core logging indicates that the predominant host mineral for the Big Mack pegmatites is petalite.
  • A thorough chain-of-custody and QA/QC program is being carried out on the ongoing drill program.
  • Samples are taken across all pegmatite intervals with shoulder samples into the host rock on either side of the dykes.
  • Sample lengths are ranging from 0.3 m – 1.5 m, dependent on internal zoning of the dykes, mineralization, and lithology contacts.

Crystal Bio Welcomes Dr. Shiaw-Lin (Billy) Wu as Co-Founder and Chief Scientific Officer

Retrieved on: 
Monday, January 29, 2024
CMC, Mass spectrometry, CSO, Biotechnology, Chromatography, GMP, Peptide, Functional, Spacecraft, LC-MS, Antibody, Protein, Dicarboxylic acid, Doctor of Philosophy, Biopharmaceutical, Proteomics, Genentech, Assay, Growth, Fine chemical

CRANBURY, N.J., Jan. 29, 2024 /PRNewswire/ -- Crystal Bio, an innovative spinout division of Crystal Pharmatech, is excited to announce Dr. Shiaw-Lin (Billy) Wu as its new co-founder and Chief Scientific Officer (CSO).

Key Points: 
  • CRANBURY, N.J., Jan. 29, 2024 /PRNewswire/ -- Crystal Bio, an innovative spinout division of Crystal Pharmatech, is excited to announce Dr. Shiaw-Lin (Billy) Wu as its new co-founder and Chief Scientific Officer (CSO).
  • We are thrilled to announce that Dr. Shiaw-Lin (Billy) Wu has joined Crystal Bio as its new co-founder and Chief Scientific Officer (CSO).
  • With over three decades of experience in analytical and bioanalytical analysis of biologics for CMC development, Dr. Wu is a valuable addition to the Crystal Bio team.
  • We are excited to have him on board and look forward to his contributions in driving innovation and growth at Crystal Bio.

New Research Hubs Established in the Greater Boston area in the US and Japan to Strengthen Support for Drug Discovery and Innovation

Retrieved on: 
Thursday, January 25, 2024
Research, Tissue, Drug discovery, 3D, Laboratory, Therapy, IPark, Shōnan, Assay, Growth

Similarly, the Nikon Healthcare R&D Center, a new research and development facility specializing in drug discovery support, has also been established at Shonan Health Innovation Park (hereafter, Shonan iPark) in Japan.

Key Points: 
  • Similarly, the Nikon Healthcare R&D Center, a new research and development facility specializing in drug discovery support, has also been established at Shonan Health Innovation Park (hereafter, Shonan iPark) in Japan.
  • Both of these innovation sites join a global network of Nikon imaging centers and laboratories through which Nikon will continue to provide product and service solutions to meet the needs of customers worldwide.
  • Harnessing all these technologies for efficient drug discovery support is a key growth driver of Nikon's medium-term management plan and requires a robust research infrastructure.
  • Through these hubs, Nikon strives to collaborate with scientists working in industry and academia to not only meet their immediate research needs, but to also drive development of cutting-edge innovations and products to meet future needs in drug discovery, basic research and healthcare.